Commission targets Lundbeck in antitrust probe
This article was originally published in SRA
Lundbeck is the latest firm to become subject to investigation for alleged anticompetitive practices by the European Commission1. The commission says it is concerned that the company may be preventing generic citalopram from entering European Union markets.
You may also be interested in...
England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.